NASDAQ:NPCE - US6412881053 - Common Stock
The current stock price of NPCE is 9.61 USD. In the past month the price increased by 8.1%. In the past year, price increased by 33.47%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 27.1 | 231.15B | ||
ISRG | INTUITIVE SURGICAL INC | 56.46 | 162.94B | ||
BSX | BOSTON SCIENTIFIC CORP | 37.91 | 158.98B | ||
SYK | STRYKER CORP | 30.69 | 150.76B | ||
MDT | MEDTRONIC PLC | 16.79 | 119.10B | ||
BDX | BECTON DICKINSON AND CO | 13.4 | 54.82B | ||
IDXX | IDEXX LABORATORIES INC | 53.33 | 51.24B | ||
EW | EDWARDS LIFESCIENCES CORP | 31.5 | 47.53B | ||
RMD | RESMED INC | 28.67 | 40.09B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 15.91 | 33.84B | ||
DXCM | DEXCOM INC | 47.51 | 31.67B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 16.51 | 26.70B |
NeuroPace, Inc. develops, manufactures, and markets implantable devices for treating epilepsy and neurological disorders. The company is headquartered in Mountain View, California and currently employs 209 full-time employees. The company went IPO on 2021-04-22. The firm is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The firm has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.
NEUROPACE INC
455 N. Bernardo Avenue
Mountain View CALIFORNIA US
CEO: Michael Favet
Employees: 209
Phone: 16502372700
The current stock price of NPCE is 9.61 USD. The price increased by 2.67% in the last trading session.
The exchange symbol of NEUROPACE INC is NPCE and it is listed on the Nasdaq exchange.
NPCE stock is listed on the Nasdaq exchange.
14 analysts have analysed NPCE and the average price target is 17.19 USD. This implies a price increase of 78.92% is expected in the next year compared to the current price of 9.61. Check the NEUROPACE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NEUROPACE INC (NPCE) has a market capitalization of 317.90M USD. This makes NPCE a Small Cap stock.
NEUROPACE INC (NPCE) currently has 209 employees.
NEUROPACE INC (NPCE) has a support level at 8.73 and a resistance level at 9.62. Check the full technical report for a detailed analysis of NPCE support and resistance levels.
The Revenue of NEUROPACE INC (NPCE) is expected to grow by 20.22% in the next year. Check the estimates tab for more information on the NPCE EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NPCE does not pay a dividend.
NEUROPACE INC (NPCE) will report earnings on 2025-11-10, after the market close.
NEUROPACE INC (NPCE) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.84).
The outstanding short interest for NEUROPACE INC (NPCE) is 3.97% of its float. Check the ownership tab for more information on the NPCE short interest.
ChartMill assigns a technical rating of 3 / 10 to NPCE. When comparing the yearly performance of all stocks, NPCE turns out to be only a medium performer in the overall market: it outperformed 44.91% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to NPCE. NPCE has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months NPCE reported a non-GAAP Earnings per Share(EPS) of -0.84. The EPS increased by 22.94% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -24.45% | ||
ROE | -133.46% | ||
Debt/Equity | 3.02 |
14 analysts have analysed NPCE and the average price target is 17.19 USD. This implies a price increase of 78.92% is expected in the next year compared to the current price of 9.61.
For the next year, analysts expect an EPS growth of 8.47% and a revenue growth 20.22% for NPCE